Agensys, Inc. Report issue

Contributed to NME For profit Phase 1 Phase 2
Founded: Santa Monica CA United States (1996)
Status: Acquired by Astellas (2007) → now Leo Pharma (2015)

Organization Overview

First Clinical Trial
2007
NCT00519233
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Carcinoma (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 1)

Carcinoma, Pancreatic Ductal (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Kidney Diseases (Phase 1)

Kidney Neoplasms (Phase 1)

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Neoplasms (Phase 1)

Ovarian Diseases (Phase 1)

Ovarian Neoplasms (Phase 1)

Pancreatic Diseases (Phase 2)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 1)

Stomach Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 17
  • # of Trial APIs: 13